New use for 1,3-propanediol derivatives

Abstract

Use of a compound of formula I wherein R 1 is an optionally substituted straight- or branched carbon chain having 12 to 22 carbon atoms which may be optionally interrupted by an optionally substituted phenylene, and each of R 2 , R 3 , R 4 and R 5 , independently, is H or lower alkyl, in free form or in pharmaceutically acceptable salt form, in the prevention or treatment of chronic rejection in a recipient of organ or tissue allo- or xenotransplant, or of acute rejection in a xenograft transplant recipient.

1 . Use of a compound of formula I  
       
         
           
           
               
               
           
         
       
       wherein 
 R 1  is an optionally substituted straight- or branched carbon chain having 12 to 22 carbon atoms which may be optionally interrupted by an optionally substituted phenylene, and  
 each of R 2 , R 3 , R 4  and R 5 , independently, is H or lower alkyl,  
 in free form or in pharmaceutically acceptable salt form,  
 in the preparation of a pharmaceutical composition for preventing or treating manifestations of chronic rejection in a recipient of organ or tissue allo- or xenotransplant.  
 
     
     
         2 . Use of a compound of formula I  
       
         
           
           
               
               
           
         
       
       wherein 
 R 1  is an optionally substituted straight- or branched carbon chain having 12 to 22 carbon atoms which may be optionally interrupted by an optionally substituted phenylene, and  
 each of R 2 , R 3 , R 4  and R 5 , independently, is H or lower alkyl,  
 in free form or in pharmaceutically acceptable salt form,  
 in the preparation of a pharmaceutical composition for preventing or treating graft vessel diseases in a recipient of organ or tissue allo- or xenotransplant.  
 
     
     
         3 . Use of a compound of formula I  
       
         
           
           
               
               
           
         
       
       wherein 
 R 1  is an optionally substituted straight- or branched carbon chain having 12 to 22 carbon atoms which may be optionally interrupted by an optionally substituted phenylene, and  
 each of R 2 , R 3 , R 4  and R5, independently, is H or lower alkyl,  
 in free form or in pharmaceutically acceptable salt form,  
 in the preparation of a pharmaceutical composition for preventing or controlling acute rejection in a xenograft transplant recipient.  
 
     
     
         4 . Use of a compound of formula I as defined in  claim 1 , in free form or in a pharmaceutically acceptable salt form, for preventing or treating manifestations of chronic rejection in a recipient of organ or tissue allo- or xenotransplant.  
     
     
         5 . Use of a compound of formula I as defined in  claim 1 , in free form or in a pharmaceutically acceptable salt form, for preventing or controlling acute rejection in a xenograft transplant recipient.  
     
     
         6 . Use according to any one of the preceding claims, wherein the compound of formula I is 2-amino-2-[2-(4-octylphenyl)ethyl]-1,3-propanediol, in free form or in pharmaceutically acceptable salt form.  
     
     
         7 . A pharmaceutical composition for preventing or treating manifestations of chronic rejection in a recipient of organ or tissue allo- or xenotransplant, or for preventing or controlling acute rejection in a xenograft transplant recipient, comprising a compound of formula I as defined in  claim 1 , in free form or in a pharmaceutically acceptable salt form, together with one or more pharmaceutically acceptable diluents or carriers therefor.  
     
     
         8 . A kit or package for preventing or treating manifestations of chronic rejection in a recipient of organ or tissue allo- or xenotransplant, or for preventing or controlling acute rejection in a xenograft transplant recipient, comprising a compound of formula I, in free form or in a pharmaceutically acceptable salt form, with a pharmaceutical composition comprising an immunosuppressant or immunomodulatory drug.  
     
     
         9 . A composition according to  claim 7  or a kit or package according to  claim 8 , wherein the compound of formula I is 2-amino-2-[2-(4-octylphenyl)ethyl]-1,3-propanediol, in free form or in pharmaceutically acceptable salt form.  
     
     
         10 . A method of preventing or treating manifestations of chronic rejection in a recipient of organ or tissue allo- or xenotransplant, or of preventing or controlling acute rejection in a xenograft transplant recipient, comprising the step of administering to said recipient a therapeutically effective amount of a compound of formula I as defined in  claim 1  in free form or in pharmaceutically acceptable salt form.